Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Therapeutics PPI Limits Policy Update | Open…
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    Proton Pump Inhibitors (PPIs) Quantity Limit Program Summary

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs quantity limits and exception approval criteria for selected proton pump inhibitors and related agents on the Boeing commercial formulary. It applies to requests for quantities exceeding the program limit, including requests supported by specified diagnoses or dosing circumstances.

    Policy Summary
    PayerPrime Therapeutics
    PolicyProton Pump Inhibitors (PPIs) Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateSep 15, 2026
    Next Review DateN/A
    Key ActionFor quantities exceeding the program limit, submit the requested dose and quantity with documentation supporting a qualifying diagnosis or dosing exception.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    60Common maximum quantity per 30 days
    30 daysStandard supply period
    12 monthsTypical approval duration
    One timeH. pylori approval duration

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    600 mL
    Konvomep maximum quantity

    Quantity-Limit Clinical Criteria

    Quantity-limit clinical criteria for approval

    The quantity limit for the target agent will be approved when ONE of the following is met:

    Quantity-limit approval pathways

    • Within program limit: The requested quantity (dose) does not exceed the program quantity limit.
    • Qualifying diagnosis

      • The patient has hypersecretory disease, including Zollinger-Ellison syndrome, Barrett's esophagitis, or esophageal stricture.
      • The patient has H. pylori.
    • Quantity exceeds limit with dosing support

      • Within maximum FDA-labeled dose

        • The requested quantity (dose) does not exceed the maximum FDA-labeled dose for the requested indication.
        • There is support for why the requested quantity (dose) cannot be achieved with a lower quantity of a higher strength that does not exceed the program quantity limit.
      • Above maximum FDA-labeled dose

        • The requested quantity (dose) exceeds the maximum FDA-labeled dose for the requested indication.
        • There is support for therapy with a higher dose for the requested indication.

    Exception Request Requirements

    Prior Authorization

    Submit an exception request for quantities above the limit

    For a quantity exceeding the program limit, submit the requested dose and quantity with documentation showing either a qualifying diagnosis, inability to achieve the dose with a lower quantity of a higher strength within the limit, or support for a higher-than-maximum FDA-labeled dose.

    Documentation Required

    Provide complete quantity-limit exception documentation

    Document the requested quantity and dose, the relevant diagnosis when applicable, the FDA-labeled dose for the indication, and clinical support for the requested exception.

    • Explain why the requested dose cannot be achieved with a lower quantity of a higher-strength product that remains within the program quantity limit.
    • If the request exceeds the maximum FDA-labeled dose, provide support for therapy with a higher dose for the requested indication.

    Qualifying Conditions

    Hypersecretory disease
    DefinitionA disorder involving excessive gastric acid secretion.
    Listed examplesZollinger-Ellison syndrome; Barrett's esophagitis; esophageal stricture.
    Quantity-limit exceptionA qualifying diagnosis may support approval of a quantity exceeding the program limit.
    H. pylori
    InfectionHelicobacter pylori (H. pylori) infection.
    Policy useTreatment of H. pylori is a qualifying diagnosis for a quantity-limit exception.
    Approval duration

    Initial Quantity-Limit Exception

    Initial quantity-limit exception

    A quantity-limit exception may be approved when ONE of the following applies:

    Initial quantity-limit approval

    • Within program limit: The requested quantity does not exceed the program quantity limit.
    • Diagnosis exception

      • Hypersecretory disease is documented, including Zollinger-Ellison syndrome, Barrett's esophagitis, or esophageal stricture.
      • H. pylori is documented.
    • Exceeds limit but within FDA-labeled dose

    Covered Product Quantity Limits

    Quantity limit
    ProductOmeprazole delayed-release capsules.
    Quantity limit60 capsules.
    Supply period30 days.
    Quantity limit
    ProductAciphex (rabeprazole sodium delayed-release tablets) 20 mg.
    Quantity limit60 tablets.
    Supply period30 days.
    Policy Summary
    PayerPrime Therapeutics
    PolicyProton Pump Inhibitors (PPIs) Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateSep 15, 2026
    Next Review DateN/A
    Key ActionFor quantities exceeding the program limit, submit the requested dose and quantity with documentation supporting a qualifying diagnosis or dosing exception.
    SourceLink
    On This Page
    Quantity-Limit Clinical CriteriaException Request RequirementsQualifying ConditionsInitial Quantity-Limit ExceptionCovered Product Quantity Limits
    Denial Risk

    Avoid denial when exceeding the quantity limit

    A quantity exceeding the applicable program limit may be denied unless the request qualifies under an approved diagnosis exception or the requested dosing and supporting rationale meet the clinical criteria.

    • Qualifying diagnoses include hypersecretory disease, including Zollinger-Ellison syndrome, Barrett's esophagitis, or esophageal stricture, and H. pylori.
    • For requests within the maximum FDA-labeled dose, explain why the dose cannot be achieved with a lower quantity of a higher strength within the limit.
    Documentation Required

    Support higher-than-labeled dosing

    Requests exceeding the maximum FDA-labeled dose must include support for therapy with a higher dose for the requested indication.

    • Document the requested quantity and dose.
    • Provide clinical support for the higher-dose therapy and identify the requested indication.
    One time for H. pylori treatment.
    The requested quantity exceeds the program limit.
  1. The requested quantity does not exceed the maximum FDA-labeled dose for the indication.
  2. Support explains why the requested quantity cannot be achieved with a lower quantity of a higher strength that does not exceed the program limit.
  3. Exceeds maximum FDA-labeled dose

    • The requested quantity exceeds the maximum FDA-labeled dose for the indication.
    • Support is provided for therapy with a higher dose for the indication.
  4. Quantity limit
    ProductDexilant (dexlansoprazole delayed-release capsules) 30 mg.
    Quantity limit60 capsules.
    Supply period30 days.
    Quantity limit
    ProductDexilant (dexlansoprazole delayed-release capsules) 60 mg.
    Quantity limit30 capsules.
    Supply period30 days.
    Quantity limit
    ProductKonvomep (omeprazole-sodium bicarbonate oral solution) 2-84 mg/mL.
    Quantity limit600 mL.
    Supply period30 days.
    Quantity limit
    ProductNexium (esomeprazole magnesium delayed-release capsules) 20 mg and 40 mg.
    Quantity limit60 capsules.
    Supply period30 days.
    Quantity limit
    ProductNexium (esomeprazole magnesium delayed-release suspension packets) 2.5 mg, 10 mg, 20 mg, and 40 mg.
    Quantity limit60 packets.
    Supply period30 days.
    Quantity limit
    ProductPrevacid (lansoprazole delayed-release capsules) 15 mg.
    Quantity limit60 capsules.
    Supply period30 days.
    Quantity limit
    ProductPrevacid SoluTab (lansoprazole delayed-release tablets) 15 mg and 30 mg.
    Quantity limit60 tablets.
    Supply period30 days.
    Quantity limit
    ProductPrilosec (omeprazole magnesium delayed-release suspension packets) 10 mg.
    Quantity limit60 packets.
    Supply period30 days.
    Quantity limit
    ProductPrilosec (omeprazole magnesium delayed-release suspension packets) 2.5 mg.
    Quantity limit60 units.
    Supply period30 days.
    Quantity limit
    ProductProtonix (pantoprazole sodium delayed-release tablets) 20 mg.
    Quantity limit60 tablets.
    Supply period30 days.
    Quantity limit
    ProductProtonix (pantoprazole sodium delayed-release suspension packets) 40 mg.
    Quantity limit60 packets.
    Supply period30 days.
    Quantity limit
    ProductRabeprazole sodium suspension packets 10 mg.
    Quantity limit60 capsules.
    Supply period30 days.
    Quantity limit
    ProductVoquezna (vonoprazan fumarate tablets) 10 mg and 20 mg.
    Quantity limit60 tablets.
    Supply period30 days.
    Quantity limit
    ProductZegerid (omeprazole-sodium bicarbonate capsules) 20-1100 mg and 40-1100 mg.
    Quantity limit60 capsules.
    Supply period30 days.
    Quantity limit
    ProductZegerid (omeprazole-sodium bicarbonate powder for suspension packets) 20-1680 mg and 40-1680 mg.
    Quantity limit60 packets.
    Supply period30 days.